PRMT5 and lymphoma: While PRMT5 inhibition showed dose-dependent anti-tumor activity in canine lymphoma cell lines, there was no significant effect on the viability of normal canine resting or activated B- or T-cells in culture, indicating that pharmacologic inhibition of PRMT5 using the small molecule inhibitor (C220) is selectively toxic to malignant cells (p < 0.